EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Epithelial Sodium Channel—An Underestimated Drug Target

Rosa Lemmens-Gruber, Susan Tzotzos iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24097775 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Rosa Lemmens-Gruber und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, A-1090 Vienna, Austria. Hauptthemen laut MEDLINE: Hypertension, Liddle Syndrome, Pseudohypoaldosteronism. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 307 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelial sodium channels (ENaC) are part of a complex network of interacting biochemical pathways and as such are involved in several disease states. Dependent on site and type of mutation, gain- or loss-of-function generated symptoms occur which span from asymptomatic to life-threatening disorders such as Liddle syndrome, cystic fibrosis or generalized pseudohypoaldosteronism type 1. Variants of ENaC which are implicated in disease assist further understanding of their molecular mechanisms in order to create models for specific pharmacological targeting. Identification and characterization of ENaC modifiers not only furthers our basic understanding of how these regulatory processes interact, but also enables discovery of new therapeutic targets for the disease conditions caused by ENaC dysfunction. Numerous test compounds have revealed encouraging results in vitro and in animal models but less in clinical settings. The EMA- and FDA-designated orphan drug solnatide is currently being tested in phase 2 clinical trials in the setting of acute respiratory distress syndrome, and the NOX1/ NOX4 inhibitor setanaxib is undergoing clinical phase 2 and 3 trials for therapy of primary biliary cholangitis, liver stiffness, and carcinoma. The established ENaC blocker amiloride is mainly used as an add-on drug in the therapy of resistant hypertension and is being studied in ongoing clinical phase 3 and 4 trials for special applications. This review focuses on discussing some recent developments in the search for novel therapeutic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionLiddle SyndromePseudohypoaldosteronismAnimalsEpithelial Sodium ChannelsAmiloride

Stichwörter der Autor:innen

Liddle syndromeTIP peptidescystic fibrosisepithelial sodium channelgain- and loss-of-function mutationspseudohypoaldosteronism type 1Bsetanaxibsolnatide

Substanzen

Epithelial Sodium ChannelsAmiloride

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, A-1090 Vienna, Austria.
  • Independent Researcher, A-1180 Vienna, Austria.

ORCID-Profile: Susan Tzotzos

Förderung

  • University of Vienna

Zitieren

APA

Lemmens-Gruber, R., & Tzotzos, S. (2023). The Epithelial Sodium Channel—An Underestimated Drug Target. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24097775

Vancouver

Lemmens-Gruber R, Tzotzos S. The Epithelial Sodium Channel—An Underestimated Drug Target. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24097775

BibTeX
@article{LemmensGruber2023,
  author = {Lemmens-Gruber, Rosa and Tzotzos, Susan},
  title = {The Epithelial Sodium Channel—An Underestimated Drug Target},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24097775}
}
Kostenlos starten →